Reversible Inhibitors of Monoamine Oxidase-A (RIMAs): Robust, Reversible Inhibition of Human Brain MAO-A by CX157

Trial Profile

Reversible Inhibitors of Monoamine Oxidase-A (RIMAs): Robust, Reversible Inhibition of Human Brain MAO-A by CX157

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Dec 2009

At a glance

  • Drugs CX 157 (Primary)
  • Indications Major depressive disorder
  • Focus Biomarker; Pharmacodynamics
  • Sponsors CeNeRx BioPharma
  • Most Recent Events

    • 07 Dec 2009 New trial record.
    • 04 Nov 2009 Results reported in Neuropsychopharmacology.
    • 04 Nov 2009 Primary endpoint 'Enzyme inhibition' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top